** Hong Kong shares of InnoCare Pharma 9969.HK jump 11.5% to HK$7.25, highest since November 13, 2024
** Shanghai-listed stock 688428.SS rises 7.1% to 13.68 yuan, highest since December 16, 2024
** China's National Medical Products Administration (NMPA) approves registrational Phase III study of drug used to treat a form of blood cancer
** Hong Kong-listed stock fell 11.2% last year, while Shanghai stock rose 6.8%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。